Literature DB >> 28820725

Understanding Hepatitis C Virus Drug Resistance: Clinical Implications for Current and Future Regimens.

David L Wyles1, Anne F Luetkemeyer2.   

Abstract

Viral resistance to direct-acting antiviral drugs may impact their effectiveness during treatment of hepatitis C virus (HCV) infection. Most data on HCV drug resistance concern genotypes 1 and 3. The clinical impact of resistance to HCV nonstructural protein 5A (NS5A) inhibitors and a practical approach to indications and methods for resistance testing are discussed.

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28820725      PMCID： PMC5935211     

Source DB:  PubMed          Journal:  Top Antivir Med        ISSN： 2161-5853


  20 in total

Review 1.  Resistance to direct antiviral agents in patients with hepatitis C virus infection.

Authors:  Christoph Sarrazin; Stefan Zeuzem
Journal:  Gastroenterology       Date:  2009-12-16       Impact factor: 22.682

2.  Infrequent development of resistance in genotype 1-6 hepatitis C virus-infected subjects treated with sofosbuvir in phase 2 and 3 clinical trials.

Authors:  Evguenia S Svarovskaia; Hadas Dvory-Sobol; Neil Parkin; Christy Hebner; Viktoria Gontcharova; Ross Martin; Wen Ouyang; Bin Han; Simin Xu; Karin Ku; Sophia Chiu; Edward Gane; Ira M Jacobson; David R Nelson; Eric Lawitz; David L Wyles; Neby Bekele; Diana Brainard; William T Symonds; John G McHutchison; Michael D Miller; Hongmei Mo
Journal:  Clin Infect Dis       Date:  2014-09-28       Impact factor: 9.079

3.  Rapid emergence of protease inhibitor resistance in hepatitis C virus.

Authors:  Libin Rong; Harel Dahari; Ruy M Ribeiro; Alan S Perelson
Journal:  Sci Transl Med       Date:  2010-05-05       Impact factor: 17.956

Review 4.  Importance of HCV genotype 1 subtypes for drug resistance and response to therapy.

Authors:  D L Wyles; J A Gutierrez
Journal:  J Viral Hepat       Date:  2014-04       Impact factor: 3.728

5.  A SPECIAL MEETING REVIEW EDITION: Advances in the Treatment of Hepatitis C Virus Infection From EASL 2015: The 50th Annual Meeting of the European Association for the Study of the Liver • April 22-26, 2015 • Vienna, AustriaSpecial Reporting on:• Daclatasvir, Sofosbuvir, and Ribavirin Combination for HCV Patients With Advanced Cirrhosis or Posttransplant Recurrence: Phase 3 ALLY-1 Study• Efficacy and Safety of Grazoprevir and Elbasvir in Hepatitis C Genotype 1-Infected Patients With Child-Pugh Class B Cirrhosis (C-SALT Part A)• Ledipasvir/Sofosbuvir With Ribavirin Is Safe and Efficacious in Decompensated and Post Liver Transplantation Patients With HCV Infection: Preliminary Results of the Prospective SOLAR 2 Trial• Retreatment of Patients Who Failed 8 or 12 Weeks of Ledipasvir/Sofosbuvir-Based Regimens With Ledipasvir/Sofosbuvir for 24 Weeks• Sofosbuvir + Peginterferon/Ribavirin for 12 Weeks Vs Sofosbuvir + Ribavirin for 16 or 24 Weeks in Genotype 3 HCV Infected Patients and Treatment-Experienced Cirrhotic Patients With Genotype 2 HCV: The BOSON Study• Safety and Efficacy of the Combination Daclatasvir-Sofosbuvir in HCV Genotype 1-Mono-Infected Patients From the French Observational Cohort ANRS CO22 HEPATHER• C-SWIFT: Grazoprevir/Elbasvir + Sofosbuvir in Cirrhotic and Noncirrhotic, Treatment-Naive Patients With Hepatitis C Virus Genotype 1 Infection for Durations of 4, 6 or 8 Weeks and Genotype 3 Infection for Durations of 8 or 12 WeeksPLUS Meeting Abstract Summaries With Expert Commentary by: Steven L. Flamm, MD Chief, Liver Transplantation ProgramProfessor of Medicine and SurgeryNorthwestern University Feinberg School of MedicineChicago, Illinois.

Authors: 
Journal:  Gastroenterol Hepatol (N Y)       Date:  2015-06

6.  All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study.

Authors:  David R Nelson; James N Cooper; Jacob P Lalezari; Eric Lawitz; Paul J Pockros; Norman Gitlin; Bradley F Freilich; Ziad H Younes; William Harlan; Reem Ghalib; Godson Oguchi; Paul J Thuluvath; Grisell Ortiz-Lasanta; Mordechai Rabinovitz; David Bernstein; Michael Bennett; Trevor Hawkins; Natarajan Ravendhran; Aasim M Sheikh; Peter Varunok; Kris V Kowdley; Delphine Hennicken; Fiona McPhee; Khurram Rana; Eric A Hughes
Journal:  Hepatology       Date:  2015-03-10       Impact factor: 17.425

7.  Resistance analysis of baseline and treatment-emergent variants in hepatitis C virus genotype 1 in the AVIATOR study with paritaprevir-ritonavir, ombitasvir, and dasabuvir.

Authors:  Preethi Krishnan; Rakesh Tripathi; Gretja Schnell; Thomas Reisch; Jill Beyer; Michelle Irvin; Wangang Xie; Lois Larsen; Daniel Cohen; Thomas Podsadecki; Tami Pilot-Matias; Christine Collins
Journal:  Antimicrob Agents Chemother       Date:  2015-06-22       Impact factor: 5.191

8.  Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection.

Authors:  Graham R Foster; Nezam Afdhal; Stuart K Roberts; Norbert Bräu; Edward J Gane; Stephen Pianko; Eric Lawitz; Alex Thompson; Mitchell L Shiffman; Curtis Cooper; William J Towner; Brian Conway; Peter Ruane; Marc Bourlière; Tarik Asselah; Thomas Berg; Stefan Zeuzem; William Rosenberg; Kosh Agarwal; Catherine A M Stedman; Hongmei Mo; Hadas Dvory-Sobol; Lingling Han; Jing Wang; John McNally; Anu Osinusi; Diana M Brainard; John G McHutchison; Francesco Mazzotta; Tram T Tran; Stuart C Gordon; Keyur Patel; Nancy Reau; Alessandra Mangia; Mark Sulkowski
Journal:  N Engl J Med       Date:  2015-11-17       Impact factor: 91.245

9.  Comparison of daclatasvir resistance barriers on NS5A from hepatitis C virus genotypes 1 to 6: implications for cross-genotype activity.

Authors:  Chunfu Wang; Lingling Jia; Donald R O'Boyle; Jin-Hua Sun; Karen Rigat; Lourdes Valera; Peter Nower; Xin Huang; Bernadette Kienzle; Susan Roberts; Min Gao; Robert A Fridell
Journal:  Antimicrob Agents Chemother       Date:  2014-06-16       Impact factor: 5.191

10.  Simeprevir plus sofosbuvir in patients with chronic hepatitis C virus genotype 1 infection and cirrhosis: A phase 3 study (OPTIMIST-2).

Authors:  Eric Lawitz; Gary Matusow; Edwin DeJesus; Eric M Yoshida; Franco Felizarta; Reem Ghalib; Eliot Godofsky; Robert W Herring; Gary Poleynard; Aasim Sheikh; Hillel Tobias; Marcelo Kugelmas; Ronald Kalmeijer; Monika Peeters; Oliver Lenz; Bart Fevery; Guy De La Rosa; Jane Scott; Rekha Sinha; James Witek
Journal:  Hepatology       Date:  2016-02-19       Impact factor: 17.425
View more
  31 in total

Review 1.  Current and future challenges in HCV: insights from an Italian experts panel.

Authors:  Massimo Andreoni; Sergio Babudieri; Savino Bruno; Massimo Colombo; Anna L Zignego; Vito Di Marco; Giovanni Di Perri; Carlo F Perno; Massimo Puoti; Gloria Taliani; Erica Villa; Antonio Craxì
Journal:  Infection       Date:  2017-11-02       Impact factor: 3.553

2.  Characterization of primary direct-acting antiviral (DAA) drugs resistance mutations in NS5A/NS5B regions of hepatitis C virus with genotype 1a and 1b from patients with chronic hepatitis.

Authors:  Ana Paula de Torres Santos; Vanessa Cristina Martins Silva; Maria Cássia Mendes-Corrêa; Marcilio Figueiredo Lemos; Fernanda de Mello Malta; Rúbia Anita Ferraz Santana; Gregório Tadeu Fernando Dastoli; Vanessa Fusco Duarte de Castro; João Renato Rebello Pinho; Regina Célia Moreira
Journal:  Rev Inst Med Trop Sao Paulo       Date:  2022-09-30       Impact factor: 2.169

3.  DAA treatment failures in a low-resource setting with a high burden of hepatitis C infections: a case series.

Authors:  Hassaan Zahid; Khawar Aslam; Elin Hoffmann Dahl; Waqas Abbassi; Suleiman Adan; Rafael Van den Bergh; Marta A Balinska; Nasir Hassan Luck
Journal:  Oxf Med Case Reports       Date:  2022-05-23

Review 4.  CROI 2018: Highlights of Viral Hepatitis.

Authors:  Anne F Luetkemeyer; David L Wyles
Journal:  Top Antivir Med       Date:  2018-05

Review 5.  Drug Design Strategies to Avoid Resistance in Direct-Acting Antivirals and Beyond.

Authors:  Ashley N Matthew; Florian Leidner; Gordon J Lockbaum; Mina Henes; Jacqueto Zephyr; Shurong Hou; Desaboini Nageswara Rao; Jennifer Timm; Linah N Rusere; Debra A Ragland; Janet L Paulsen; Kristina Prachanronarong; Djade I Soumana; Ellen A Nalivaika; Nese Kurt Yilmaz; Akbar Ali; Celia A Schiffer
Journal:  Chem Rev       Date:  2021-01-07       Impact factor: 60.622

6.  Glecaprevir/pibrentasvir+sofosbuvir: an optimal retreatment strategy in the setting of HCV NS5A resistance.

Authors:  Arshia Alimohammadi; Brian Conway; Leo Yamamoto
Journal:  BMJ Case Rep       Date:  2020-02-11

Review 7.  Antiviral Activity Exerted by Natural Products against Human Viruses.

Authors:  Maria Musarra-Pizzo; Rosamaria Pennisi; Ichrak Ben-Amor; Giuseppina Mandalari; Maria Teresa Sciortino
Journal:  Viruses       Date:  2021-05-04       Impact factor: 5.048

Review 8.  Applications of Deep Mutational Scanning in Virology.

Authors:  Thomas D Burton; Nicholas S Eyre
Journal:  Viruses       Date:  2021-05-28       Impact factor: 5.048

Review 9.  A Focused Review on Recent Advances in the Diagnosis and Treatment of Viral Hepatitis.

Authors:  Wei Zhang; Mahmoud Aryan; Steve Qian; Roniel Cabrera; Xiuli Liu
Journal:  Gastroenterology Res       Date:  2021-06-19

10.  Prevalence of Single and Multiple Natural NS3, NS5A and NS5B Resistance-Associated Substitutions in Hepatitis C Virus Genotypes 1-4 in Italy.

Authors:  Ada Bertoli; Maria Chiara Sorbo; Marianna Aragri; Ilaria Lenci; Elisabetta Teti; Ennio Polilli; Velia Chiara Di Maio; Laura Gianserra; Elisa Biliotti; Chiara Masetti; Carlo F Magni; Sergio Babudieri; Laura A Nicolini; Martina Milana; Pierluigi Cacciatore; Loredana Sarmati; Adriano Pellicelli; Stefania Paolucci; Antonio Craxì; Filomena Morisco; Valeria Pace Palitti; Massimo Siciliano; Nicola Coppola; Nerio Iapadre; Massimo Puoti; Giuliano Rizzardini; Gloria Taliani; Caterina Pasquazzi; Massimo Andreoni; Giustino Parruti; Mario Angelico; Carlo Federico Perno; Valeria Cento; Francesca Ceccherini-Silberstein
Journal:  Sci Rep       Date:  2018-06-12       Impact factor: 4.379
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.